~~<i id='2C047C3F05'><strike id='2C047C3F05'><tt id='2C047C3F05'><pre id='2C047C3F05'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

comprehensive

author：comprehensive 2025-09-29 13:46:16 - browse：224

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： The real point of Kenneth Smith’s execution by nitrogen gas

knowledge

leisure time

knowledge

entertainment

hotspot

AdoseofmethadoneKevinD.Liles/APThefederalgovernmentisreformingmethadonecareforthefirsttimeinovertwod

WSS

UnitedHealth increases loan offers after Change Healthcare outage

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Do digital therapeutics have a future in medicine?

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Stop the failed accountable care organization experiment

Cybersecurity threat forces Lurie Children's to take systems offline

explore

comprehensive

knowledge

Guidelines to prevent youth baseball injuries need more muscle

SCOTUS questions limit to govt efforts to fight misinformation

Alkermes shareholders re

Plastic surgeons increase patient psychiatric screenings

In Memoriam: Notable people who died in 2023

Neuroscience’s long legacy of racism

New air purifier tech could be key to improving indoor air quality

Leading voice in opioid treatment defends methadone clinic system

Duchenne breakthrough therapy leaves behind pioneering families

Baby aspirin cuts fat buildup in liver disease patients, in small study

leisure time

Quicker fix for pulse oximeters urged during FDA public meeting

5 to watch: Tech startups trying to solve health care's staffing crisis

SAMSHA loosens regulations on methadone treatment centers

Even great ERs can’t make up for American health disparities

U.K. researchers warn about biases in medical devices, algorithms

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

knowledge

entertainment

entertainment

hotspot